The structure provided by KDOQI-CKD was an advance from the preceding nosologic chaos and it quickly became embedded in the lexicon of clinical nephrology. However, it was not long before some disquieting observations led to challenges to the uncritical application of the KDOQI-CKD schema to the diagnosis of CKD in the community at large [3, 4, 5 ] . Although these observations may erode some of the fundamental assumptions of the CKD classification system, they do not negate the need for a systematic approach to the nondisease-specific identification and classification of CKD, especially for epidemiological and prognostic purposes. The latter has been the focus of a recent conference designed to examine the relationship between CKD staging and outcome and to further refine the classification schema (KDIGO Controversies Conference-Chronic Kidney Disease: Definition, Classification and Prognosis; London, UK, 4-6 October 2009). Here, we will focus on the flaws inherent to the current diagnostic schema for CKD and will suggest how they might be eliminated. Some commentators even question whether identification of CKD, as presently defined, can logically be called a 'diagnosis' at all, as it is so disease nonspecific. Thus, the presence of features of CKD may be a step in the process of diagnosis, but not in-and-of-itself 'diagnostic'. Although CKD is a useful concept from an epidemiological perspective, its meaning for individual patients is limited by its disease nonspecificity.
The glomerular filtration rate component of chronic kidney disease diagnosis
The KDOQI-CKD schema recommends the use of an estimated value of GFR (eGFR) rather than the actual or measured GFR (mGFR) for diagnosis and staging of CKD [2 , [6] [7] [8] [9] . This seems sensible, as actual measurement of GFR (mGFR) can be cumbersome and timeconsuming and not generally applicable to communitybased screening or to epidemiological studies. However, mGFR values are needed when it is essential to exclude the presence of 'kidney disease' [10, 11 ] . The estimation of GFR was to be based on the use of formulas utilizing serum creatinine concentration as the marker of GFR. The eGFR formula of the Modification of Diet in Renal Disease (MDRD), abbreviated four variable equation [6] or the Cockcroft-Gault formula for estimating endogenous creatinine clearance [eCcr (C-G)] [7] were suggested in adults and the Schwartz and Counahan equations in children [2 ] . The eGFR (MDRD) equation became the most widely used, but for more accurate results, the serum creatinine needed to be 'calibrated' to a MDRD standard. Later versions of this formula were adapted to an international mass-based standard in the United States [8] . The eCcr (C-G) did not provide a comparable estimate of GFR, as it generates an approximation of endogenous creatinine clearance, which is known to be higher than GFR, by a factor of about 1.2 in normal individuals, independent of age, due to tubular secretion of creatinine [12] . The value of eGFR (MDRD) is adjusted to a standard body surface area (BSA) (1.73 m 2 ) within the equation, whereas the eCcr (C-G) equation includes body weight as a variable and does not adjust the final value for BSA. It is dubious mathematics to adjust the eCcr (C-G) for BSA, as the equation already contains a variable for the weight component of BSA. Adjustment for BSA can also lead to errors in classification of CKD in the very obese and in the very lean [13] .
Both of these estimating equations for GFR utilize variables in the equations [age, sex, and race (black vs. nonblack) in eGFR (MDRD) and age, body weight, and sex in eCcr (C-G)] as 'surrogates' for endogenous creatinine production. These formulas do not intrinsically 'correct' for the normal decline of GFR with aging according to sex [14 ,15 ] . The endogenous 'pro-duction' rate of creatinine is governed chiefly by lean body (muscle) mass and to a lesser extent by creatinine absorption from meat (cooked) in the diet and by creatinine degradation in the gut. Herein lays a possible source of error in the use of estimating formulas for GFR in the diagnosis of CKD. The participants used for generating the estimating equations all had stable or slowly progressive established CKD, not defined by KDOQI-CKD criteria. None was seriously malnourished, acutely ill, or consistently ingesting a creatinine-free diet (vegetarian). When creatinine 'generation' is likely to be lower than expected (due to sarcopenia or low creatinine absorption in the intestine) the resulting lower level of serum creatinine will lead to an overestimation of GFR. Compared with mGFR, the eGFR (MDRD) systematically underestimates mGFR (negative bias), whereas eCcr (C-G) tends to overestimate the mGFR particularly at higher levels of mGFR (>60 ml/min per 1.73 m 2 ) [16 ] . Both formulas also potentially overestimate mGFR in the presence of marked proteinuria and hypo-albuminemia (nephrotic syndrome) [17] and also in severe renal failure (stage 5 CKD) [16 ] .
An even more serious flaw in the original estimating formulas is their lack of precision relative to mGFR, as measure by the standard deviation of the estimate, particularly at higher levels of mGFR [16 ,18] . This lack of precision and the presence of bias leads to incorrect classification (diagnosis) of CKD in about 20-30% of patients compared with a reference standard of mGFR [16 ,18] . Newer variations of the original eGFR (MDRD) formula have been devised to partially correct this deficiency (e.g., the CKD-EPI equations) [19 ] . These formulas have reduced bias, particularly in the higher ranges of eGFR and improved accuracy, but have not provided much better precision. In addition, new estimating equations for GFR utilizing a noncreatinine reference have been studied in normal individuals and in those with CKD, especially cystatin C [eGFR (CyC)] [20, 21 ] . Combinations of the eGFR (MDRD) and the eGFR (CyC) have also been used, but whether they have improved accuracy compared with the standard estimates of eGFR is debated [22] .
The most clinically relevant defect and controversial of the pitfalls in the GFR component of the current diagnostic and staging criteria for CKD arises from the use of an arbitrary threshold for eGFR values as being 'diagnostic' of CKD and the separation of stages based on the calculated values for eGFR. In KDOQI-CKD, a 'diagnosis' of stage 3 CKD, in an adult of any age, can be made if the eGFR (MDRD) was between 30 and 59 ml/min per 1.73 m 2 and persists for 3 months or longer, even in the total absence of any corroborating signs of 'kidney damage', including albuminuria [2 ]. The rationale underlying the selection of this 'threshold' was that it is approximately 50% of the 'normal' level of GFR of an average adult of 20 years of age. This threshold fails to take into account the usual and probably normal decline of GFR seen with aging [14 ,15 ] . The rate of change in GFR with aging is about 8-10 ml/min per 1.73 m 2 per decade. It can be argued that this decline in GFR associated with aging is a consequence of complications of aging, affecting the kidneys, and, therefore, reflects true 'kidney disease'. A counter argument, which we prefer, is that this decline is part and parcel of normal senescence [15 ] . If a decline in GFR universally occurs with aging, even in the absence of any visible evidence of a complication of aging (e.g., hypertension, diabetes, prostatism, arteriolosclerosis), then why should it be designated as a form of 'chronic kidney disease'? Every cross-sectional study of GFR (mGFR or eGFR) in apparently healthy community-living adults has shown this secular decline of GFR with aging [14 ,15 ] . The very few longitudinal studies conducted in such individuals have shown that the change in eGFR is normally distributed in aging populations; no dichotomy is observed in these frequency distribution analyses as would be predicted if there are subsets of diseased and nondiseased of aging individuals within these cohorts [23] . But not everyone agrees that a decline in GFR with aging is inevitable [24] . This is more than a semantic argument -it relates to the fundamental biology of the aging process itself and the dividing line between health and disease. Sickness, ill health and disease should confer some disadvantage (premature mortality, morbidity) upon the individual. As will be discussed below, such a disadvantage does not appear to be conferred on an elderly patient with stage 3 CKD and higher levels of eGFR (e.g., eGFR 45-59 ml/min per 1.73 m 2 ), in the absence of albuminuria or some other sign of 'kidney damage'. Elderly patients with eGFR less than 45 ml/min per 1.73 m 2 likely do have some associated increase in risk of mortality and development of ESRD. However, another observation is also true -a much younger person with an isolated eGFR value in the range of stage 3 CKD, or even higher (as defined by KDOQI-CKD), almost certainly has some underlying kidney disease. In our opinion, the diagnosis of CKD should not rest solely on an isolated lowering of eGFR without adjustment for the normal decline in GFR with aging, preferably using established percentiles of GFR according to decades of age in apparently healthy community-living adults. The use of such percentiles for adjustment of the effects of age is common in diagnosis of osteoporosis in adult women, the evaluation of pulmonary function tests, and growth retardation in children. If one uses the eGFR (MDRD) for 'diagnosis' or 'staging' of CKD, the applicability of the formula to diverse ancestral populations, customary diets, and prevailing muscle mass must also be taken into account Finally, the separation of stage 1 CKD (eGFR 90 ml/ min per 1.73 m 2 ) and stage 2 CKD (60-89 ml/min per 1.73 m 2 ) based on eGFR values cannot be justified, in our view, because of the inaccuracy of eGFR measurements above 60 ml/min per 1.73 m 2 (see above). We have made suggestions on how to deal with the pitfalls in the use of eGFR to diagnose CKD elsewhere [25 ] . It seems likely that the uncritical use of the KDOQI-CKD (2002) and eGFR (MDRD) criteria for diagnosis of stage 3 CKD will lead to a large number of 'false-positive' diagnoses of CKD, particularly in older women and lead to much unnecessary referral, investigations, costs, and anxiety [3,4,5 ,25 ,26 ] . It also greatly inflates the estimates of the prevalence of CKD on a global basis, particularly in societies with a relatively higher proportion of older citizens [27] . It should also be pointed out that nearly every individual (without severe malnutrition or sarcopenia) with an eGFR less than 45 ml/min per 1.73 m 2 will also have an abnormally elevated serum creatinine concentration, regardless of age. Even a simple serum creatinine level, without any calculation of eGFR, may be sufficient for the 'diagnosis' of stage 3 CKD and greater, if appropriate sex-specific threshold values for serum creatinine concentration are utilized [28, 29] .
In sum, in our opinion, eGFR values, viewed in isolation, should primarily be for staging of the severity CKD and for 'risk-stratification', following the diagnosis of a specific disease state causing CKD, not for the initial diagnosis of generic CKD. Moreover, the diagnostic use of eGFR should only be applied after adjusting the threshold values for staging according to age and sex by the use of percentiles of the normal distribution the values of eGFR in a healthy (nondiseased) reference population. Thus, the diagnosis of generic CKD should largely rest on signs of 'kidney damage' with staging to follow. We believe that eGFR is a deceptively simple but blunt epidemiological tool and is not sufficiently accurate for the diagnosis of CKD as a sole criterion. Values for eGFR alone should not, in our opinion, be used to rule in the diagnosis of CKD without any corroborating signs of 'kidney damage' unless they are below 30 ml/min per 1.73 m 2 , but they can be used, along with imaging and urinalysis, to exclude a diagnosis of CKD. Values of eGFR alone should not be used to rule out CKD. Individuals who have values of eGFR below the 5th percentile (adjusted for age and sex) who also have a normal urinalysis should be investigated further for signs of kidney damage. It is not recommended that eGFR be used for screening of apparently healthy individuals for the presence of CKD, unless albuminuria is concomitantly assessed.
The staging of the severity of CKD and the risk of complications, such as cardiovascular disease (CVD), acute kidney injury (AKI), and development of ESRD, may be aided by eGFR measurements, so long as it is recognized that the precision and bias of the test limits Diagnosing chronic kidney disease Glassock and Winearls 125 the accuracy of the staging process, especially at levels of eGFR more than 45-60 ml/min per 1.73 m 2 .
The kidney damage component of chronic kidney disease diagnosis
Less doubt exists regarding the validity of a diagnosis of CKD when one finds (and confirms over a 3-month period of observation) an abnormality in a urinalysis (e.g., overt glomerular or tubular proteinuria, glomerular hematuria, red cell casts, and other formed elements indicative of parenchymal renal disease), in imaging (ultrasound, CT or MRI), or in a renal biopsy. These are time-honored methods for the diagnosis of kidney disease and of parsing the responsible specific disease entity. However, the bar has been lowered by using the rate of albumin excretion or its concentration in urine as a means of diagnosing CKD. This is radical and controversial. There is broad agreement that a finding of excretion more than 300 mg per day of protein or albumin (AER) in a timed collection of urine or a value of the albumin-to-creatinine concentration ratio (ACR) of more than 250 mg/g (men) or more than 350 mg/g (women) or a protein-to-creatinine concentration ratio of more than 200 mg/g in an untimed urine collection (second morning void) is reliably indicative of 'kidney damage' [2 ] . These values correspond to a 1þ or greater value on a urinary 'dipstick' test (after taking into consideration the specific gravity or osmolality of the specimen). This clinical or overt proteinuria is appropriately an integral part of the diagnosis of stage 1 and 2 CKD (but not stages 3-5 CKD) in the KDOQI-CKD construct [2 ]. However, the KDOQI-CKD construct goes one step (or leap in our judgment) further -it includes 'microalbuminuria' [30-300 mg per day or 17-250 mg albumin/g creatinine (men) or 25-350 mg albumin/g creatinine (women)] in defining stages 1 and 2 CKD, irrespective of the prevailing level of eGFR above 60 ml/min per 1.73 m 2 . This value of albumin excretion would give a reading of less than 1þ on a 'dipstick'. In the National Health and Nutrition Examination Surveys (NHANES) in the United States, approximately 82% of the patients 'diagnosed' as having stage 1 or 2 CKD had 'microalbuminuria' as the qualifying abnormality for classifying them in the stages of CKD [30] .
Although 'microalbuminuria' is obviously a marker of a process occurring within the kidneys, dispute exists as to whether it is glomerular or tubular or both in origin [31] . We would opine that this inclusion inflates the likelihood of a diagnosis of CKD and that it is primarily a sign of diffuse (systemic) endothelial vascular injury engendered by microinflammation. In this formulation, 'microalbuminuria' is a marker of a diffuse pathobiological process affecting the capillary beds of many organs and tissues. As such, it is more of a 'risk factor' for a systemic vascular disease process rather than a sign of 'disease' of the kidneys per se. It has been well documented that any degree of albuminuria above the normal range is associated with an increased risk of CVD and ESRD [32 ,33 ,34] . To illustrate the point, 'microalbuminuria' develops as a part of aging, excess weight gain, essential hypertension, diabetes, and superimposed inflammatory states [35] [36] [37] . It can come and go, implying reversibility of the injury, which cannot, therefore, be chronic. 'Microalbuminuria' is a common feature of 'incipient' diabetic nephropathy, and urinary albumin excretion increases before the development of fixed essential hypertension or ischemic heart disease [38, 39] , but is its solitary presence sufficient to label any individual of any age as having CKD? We think not. Albuminuria is a 'risk factor' not a 'disease'.
The consequences of a diagnosis of chronic kidney disease
The diagnosis of stages 1-4 CKD can imply a risk for future progression to end-stage renal disease (ESRD; stage 5 CKD) requiring renal replacement therapy (RRT; dialysis or transplantation or both). It may also confer a risk of CVD and AKI. The risk of ultimately developing ESRD varies widely according to the stages and the individual disease-specific characteristics of the patient. Older individuals with stage 3 CKD (as defined by KDOQI-CKD) are far more likely to die, usually of CVD, than to reach treated ESRD. The risk of reaching treated ESRD is inversely related to age, due to competing mortality [40, 41] . The risk of an elderly patient with stage 3 CKD reaching treated ESRD is about 0.2-0.4% per year of follow-up [40] . Concomitant proteinuria greatly magnifies this risk [42 ,43] . In addition, the risk of CVD events and all-cause mortality are increased in CKD, but the extent of the additional risk, after adjustment for covariates, differs widely according to the stage of CKD and in particular whether concomitant overt proteinuria is present [44 ] . The PREVEND study has shown the CVD mortality risk is inversely related to stage of CKD [33 ] . The risk for CVD death in individuals with stage 3 CKD (KDOQI-CKD) with an eGFR 30-59 ml/min per 1.73 m 2 who do not have concomitant proteinuria is approximately the same as those with no CKD at all [33 ] . Examination of large patient databases has also suggested that there is an inverse nonlinear association (often 'U' shaped) between eGFR and CVD or all-cause mortality risk [44 ] . This topic was the subject of an intense examination at the recently concluded KDIGO Controversies Conference in London mentioned above. A threshold for increased risk of CVD exclusively associated with reduced GFR (without proteinuria) is hard to firmly establish, but may be in the vicinity of 45-60 ml/min per 1.73 m 2 , perhaps below the qualifying threshold for diagnosing stage 3 CKD by eGFR used by KDOQI. Albumin excretion varies independently of eGFR in population studies [45] and both are additive or synergistic in terms of risk for CVD (and ESRD) [42 ,44 ] . We interpret these observations as indicating that albuminuria may be more important in determining outcomes in terms of CVD and ESRD than the absolute level of eGFR, but his requires further study in large well defined cohorts.
It is well known that the frequency of signs of complications of CKD (such as vitamin D deficiency, anemia, hypertension, renal bone disease, hyperparathyroidism, and hyperphosphatemia)increaseaspatients'progress'through the stages of CKD [46] . These observations largely rest on cross-sectional studies rather than longitudinal studies of cohorts of individual patients. The development of these 'complications' of CKD may not appear simultaneously in the 'progress' of CKD along its 'stages'.
It is disappointing to observe that the promise of prevention of the complications of CKD or a delay in the adverse outcomes associated with CKD (such as CVD or ESRD) through early detection have yet to be realized. Screening for CKD by means of assessing eGFR has not yet been proven to be cost-effective [26 ] .
A role for population-based screening for 'microalbuminuria ' has not yet been firmly established, due to uncertainties regarding the 'false positive' and 'false negative' rates, and the variability of ACR in superimposed acute illness, aging and loss of muscle mass.
Conclusion
Diagnosing CKD is a complex task that cannot be simplified by relying on measurement of eGFR. The original KDOQI-CKD construct, although conceptually novel and transforming, has many pitfalls that can lead to both underdiagnosis and overdiagnosis of CKD in individuals as well as in population-based studies. It needs further refinement to make it a more practical clinical tool having greater prognostic utility. One can challenge whether CKD is an authentic diagnosis, as it is so generic and nondisease specific, by intent and design. Nevertheless, CKD is already deeply embedded in the lexicon of nephrology. The challenge is how to make the designation of CKD more meaningful and accurate for prognosis in individual patients and for the assessment of the population burden of disease.
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